A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO ASSESS SAFETY AND EFFICACY OF SLS-005 (TREHALOSE INJECTION, 90.5 MG/ML FOR INTRAVENOUS INFUSION) FOR THE TREATMENT OF ADULTS WITH SPINOCEREBELLAR ATAXIA

Spinocerebellar Ataxia type-3 (SCA3)

Change from baseline in m-SARA total score at Week 52 in participants with SCA3 treated with SLS-005 0.75 g/kg compared to placebo

Key Secondary Endpoints In participants treated with SLS-005 0.75 g/kg: • Change from baseline in Clinical Global Impression of Severity (CGI-S) at Week 52, • Change from baseline in Patient Global Impression of Severity (PGI-S) at Week 52, • Change from baseline in Friedreich’s Ataxia Rating Scale – Activities of Daily Living (FARS-ADL) score at Week 52, • Change from baseline in m-SARA total score at Week 26, Secondary Endpoints In participants with treated with SLS-005 0.75 g/kg: • Changes from baseline in m-SARA total score at Weeks 4, 13, and 39, • Changes from baseline in CGI-S at Weeks 4, 13, 26, and 39, • Changes from baseline in PGI-S at Weeks 4, 13, 26, and 39, • Changes from baseline in FARS-ADL score at Weeks 4, 13, 26, and 39, • Changes from baseline in scores for each item of the m-SARA at Weeks 4, 13, 26, 39, and 52, In all participants: • Incidences of treatment-emergent adverse events (TEAEs) and SAEs, including clinically significant laboratory and ECG abnormalities

No related papers found yet.

Germany, Portugal, Spain